If it hadn't been for the pandemic, the past year would have likely been dominated by a familiar topic - Brexit. The decision to leave, we're told, presents the UK with endless opportunity in a variety of sectors, including healthcare and life sciences. But it hasn't been the easiest year, with supply chains and the Northern Ireland Protocol already under strain. So what are the opportunities to boost Britain's healthcare now that it has left the EU, and where are the pitfalls?
Kate Andrews is joined by Antonis Papasolomontos, Director of External Affairs at Abbvie, Sarah Neville, Global Health Editor at the FT, and Jeremy Hunt, Chair of the Health Select Committee.
Sponsored by Abbvie.